drugset / Trial / NCT00033644
Combination Chemotherapy Plus Sargramostim in Treating Patients With Cancer of the Uterus
Treatment
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Colony-stimulating factors such as sargramostim may increase the number of immune cells found in bone marrow or peripheral blood and may help a person's immune system recover from the side effects of chemotherapy. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy plus sargramostim in treating patients who have advanced, persistent, or recurrent cancer of the uterus.
Timeline
- Start
- 2002-03
- Primary completion
- 2005-10
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cisplatin | Other / unclassified | 60 mg/m2 | Intravenous |
| Subject | Dacarbazine | Small molecule | 750 mg/m2 | Intravenous |
| Subject | Doxorubicin | Other / unclassified | 40 mg/m2 | — |
| Subject | Mitomycin C | Other / unclassified | 6 mg/m2 | Intravenous |
| Subject | sargramostim | Protein / enzyme biologic | 250 ug/m2 | Subcutaneous |